CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme.

MLA

Radtke, Lena, et al. “CRISPR/Cas9-Induced Knockout Reveals the Role of ABCB1 in the Response to Temozolomide, Carmustine and Lomustine in Glioblastoma Multiforme.” Pharmacological Research, vol. 185, Nov. 2022, p. 106510. EBSCOhost, https://doi.org/10.1016/j.phrs.2022.106510.

APA

Radtke, L., Majchrzak-Celińska, A., Awortwe, C., Vater, I., Nagel, I., Sebens, S., Cascorbi, I., & Kaehler, M. (2022). CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme. Pharmacological Research, 185, 106510. https://doi.org/10.1016/j.phrs.2022.106510

Chicago

Radtke, Lena, Aleksandra Majchrzak-Celińska, Charles Awortwe, Inga Vater, Inga Nagel, Susanne Sebens, Ingolf Cascorbi, and Meike Kaehler. 2022. “CRISPR/Cas9-Induced Knockout Reveals the Role of ABCB1 in the Response to Temozolomide, Carmustine and Lomustine in Glioblastoma Multiforme.” Pharmacological Research 185 (November): 106510. doi:10.1016/j.phrs.2022.106510.